Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study - Concepedia

Concepedia

Publication | Open Access

Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study

DOI Full Paper Access

60

Citations

10

References

2023

Year

Pierfrancesco Tassone, Maria Teresa Di Martino, Mariamena Arbitrio, Lucia Fiorillo, Nicoletta Staropoli, Domenico Ciliberto, A. Cordua, Francesca Scionti, Bernardo Bertucci, Angela Salvino,

Journal of Hematology & Oncology

References

	Year	Citations

Page 1